STERIS plc Logo

STERIS plc

STE

(2.8)
Stock Price

238,38 USD

13.15% ROA

9.12% ROE

40.23x PER

Market Cap.

22.127.786.793,00 USD

55.54% DER

0.88% Yield

10.48% NPM

STERIS plc Stock Analysis

STERIS plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

STERIS plc Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (47%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

3 Dividend Growth

The company has demonstrated exceptional dividend growth over the past five years, consistently increasing payouts to shareholders year after year.

4 Dividend

The company's consistent dividend distribution over the past five years reflects its dedication to providing shareholders with steady returns, making it an appealing choice for investors seeking income stability.

5 ROE

The stock's ROE falls within an average range (1.98%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

6 ROA

The stock's ROA (2.96%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

7 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (13.457), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

8 PBV

The stock's elevated P/BV ratio (3.2x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

9 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

10 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

11 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

STERIS plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

STERIS plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

STERIS plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

STERIS plc Revenue
Year Revenue Growth
1991 8.800.000
1992 12.900.000 31.78%
1993 26.700.000 51.69%
1994 45.800.000 41.7%
1995 64.300.000 28.77%
1996 91.200.000 29.5%
1997 587.900.000 84.49%
1998 719.656.000 18.31%
1999 797.600.000 9.77%
2000 760.626.000 -4.86%
2001 800.087.000 4.93%
2002 866.697.000 7.69%
2003 972.087.000 10.84%
2004 1.087.012.000 10.57%
2005 1.119.745.000 2.92%
2006 1.160.285.000 3.49%
2007 1.197.407.000 3.1%
2008 1.265.090.000 5.35%
2009 1.298.525.000 2.57%
2010 1.257.733.000 -3.24%
2011 1.207.448.000 -4.16%
2012 1.391.504.000 13.23%
2013 1.501.902.000 7.35%
2014 1.622.252.000 7.42%
2015 1.850.263.000 12.32%
2016 2.238.764.000 17.35%
2017 2.612.756.000 14.31%
2018 2.619.996.000 0.28%
2019 2.782.170.000 5.83%
2020 3.030.895.000 8.21%
2021 3.107.519.000 2.47%
2022 4.585.064.000 32.23%
2023 4.957.839.000 7.52%
2024 5.369.440.000 7.67%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

STERIS plc Research and Development Expenses
Year Research and Development Expenses Growth
1991 0
1992 0 0%
1993 0 0%
1994 0 0%
1995 6.700.000 100%
1996 8.300.000 19.28%
1997 22.000.000 62.27%
1998 23.914.000 8%
1999 24.800.000 3.57%
2000 24.169.000 -2.61%
2001 23.975.000 -0.81%
2002 21.706.000 -10.45%
2003 25.525.000 14.96%
2004 28.454.000 10.29%
2005 35.547.000 19.95%
2006 33.597.000 -5.8%
2007 33.626.000 0.09%
2008 36.916.000 8.91%
2009 32.760.000 -12.69%
2010 34.008.000 3.67%
2011 34.280.000 0.79%
2012 35.953.000 4.65%
2013 41.305.000 12.96%
2014 48.641.000 15.08%
2015 54.139.000 10.16%
2016 56.664.000 4.46%
2017 59.397.000 4.6%
2018 60.782.000 2.28%
2019 63.038.000 3.58%
2020 65.546.000 3.83%
2021 66.326.000 1.18%
2022 87.944.000 24.58%
2023 101.581.000 13.42%
2024 108.176.000 6.1%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

STERIS plc General and Administrative Expenses
Year General and Administrative Expenses Growth
1991 0
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

STERIS plc EBITDA
Year EBITDA Growth
1991 400.000
1992 200.000 -100%
1993 2.400.000 91.67%
1994 8.100.000 70.37%
1995 13.700.000 40.88%
1996 21.300.000 35.68%
1997 187.200.000 88.62%
1998 136.816.000 -36.83%
1999 168.100.000 18.61%
2000 69.378.000 -142.3%
2001 117.316.000 40.86%
2002 127.497.000 7.99%
2003 172.284.000 26%
2004 189.039.000 8.86%
2005 196.185.000 3.64%
2006 218.233.000 10.1%
2007 211.126.000 -3.37%
2008 217.245.000 2.82%
2009 239.375.000 9.24%
2010 213.408.000 -12.17%
2011 99.009.000 -115.54%
2012 234.812.000 57.83%
2013 208.135.000 -12.82%
2014 233.215.000 10.75%
2015 226.429.000 -3%
2016 211.287.000 -7.17%
2017 344.737.000 38.71%
2018 403.660.000 14.6%
2019 473.439.000 14.74%
2020 538.319.000 12.05%
2021 542.540.000 0.78%
2022 425.714.000 -27.44%
2023 1.250.285.000 65.95%
2024 743.428.000 -68.18%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

STERIS plc Gross Profit
Year Gross Profit Growth
1991 5.400.000
1992 7.300.000 26.03%
1993 16.000.000 54.38%
1994 28.600.000 44.06%
1995 41.600.000 31.25%
1996 59.100.000 29.61%
1997 248.400.000 76.21%
1998 324.558.000 23.47%
1999 401.900.000 19.24%
2000 355.097.000 -13.18%
2001 374.511.000 5.18%
2002 355.201.000 -5.44%
2003 408.821.000 13.12%
2004 457.899.000 10.72%
2005 471.651.000 2.92%
2006 484.185.000 2.59%
2007 504.807.000 4.09%
2008 523.957.000 3.65%
2009 526.742.000 0.53%
2010 539.182.000 2.31%
2011 446.162.000 -20.85%
2012 568.465.000 21.51%
2013 621.263.000 8.5%
2014 649.622.000 4.37%
2015 774.301.000 16.1%
2016 895.481.000 13.53%
2017 1.025.632.000 12.69%
2018 1.094.223.000 6.27%
2019 1.175.427.000 6.91%
2020 1.319.923.000 10.95%
2021 1.343.100.000 1.73%
2022 2.016.362.000 33.39%
2023 2.159.692.000 6.64%
2024 2.374.116.000 9.03%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

STERIS plc Net Profit
Year Net Profit Growth
1991 0
1992 0 0%
1993 2.500.000 100%
1994 6.300.000 60.32%
1995 8.700.000 27.59%
1996 12.800.000 32.03%
1997 -30.600.000 141.83%
1998 65.496.000 146.72%
1999 84.900.000 22.86%
2000 10.485.000 -709.73%
2001 1.317.000 -696.13%
2002 46.202.000 97.15%
2003 79.436.000 41.84%
2004 94.243.000 15.71%
2005 85.980.000 -9.61%
2006 70.289.000 -22.32%
2007 82.155.000 14.44%
2008 77.106.000 -6.55%
2009 110.685.000 30.34%
2010 128.467.000 13.84%
2011 51.265.000 -150.59%
2012 136.115.000 62.34%
2013 159.977.000 14.92%
2014 129.442.000 -23.59%
2015 135.064.000 4.16%
2016 110.763.000 -21.94%
2017 109.965.000 -0.73%
2018 290.915.000 62.2%
2019 304.051.000 4.32%
2020 407.605.000 25.41%
2021 397.400.000 -2.57%
2022 243.888.000 -62.94%
2023 107.030.000 -127.87%
2024 461.276.000 76.8%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

STERIS plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1991 0
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 1 100%
2000 0 0%
2001 0 0%
2002 1 0%
2003 1 100%
2004 1 0%
2005 1 0%
2006 1 0%
2007 1 0%
2008 1 0%
2009 2 0%
2010 2 50%
2011 1 0%
2012 2 100%
2013 3 0%
2014 2 0%
2015 2 0%
2016 2 -100%
2017 1 0%
2018 3 66.67%
2019 4 0%
2020 5 25%
2021 5 0%
2022 3 -100%
2023 1 -100%
2024 5 75%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

STERIS plc Free Cashflow
Year Free Cashflow Growth
1991 -800.000
1992 -2.300.000 65.22%
1993 -300.000 -666.67%
1994 200.000 250%
1995 -3.800.000 105.26%
1996 -4.600.000 17.39%
1997 -4.200.000 -9.52%
1998 -27.188.000 84.55%
1999 -54.200.000 49.84%
2000 -6.024.000 -799.73%
2001 51.322.000 111.74%
2002 76.345.000 32.78%
2003 74.699.000 -2.2%
2004 55.742.000 -34.01%
2005 95.222.000 41.46%
2006 110.785.000 14.05%
2007 46.716.000 -137.15%
2008 86.427.000 45.95%
2009 126.495.000 31.68%
2010 180.867.000 30.06%
2011 40.302.000 -348.78%
2012 82.690.000 51.26%
2013 140.403.000 41.11%
2014 123.264.000 -13.9%
2015 160.785.000 23.34%
2016 128.268.000 -25.35%
2017 251.185.000 48.93%
2018 292.175.000 14.03%
2019 349.790.000 16.47%
2020 376.043.000 6.98%
2021 450.378.000 16.51%
2022 397.248.000 -13.37%
2023 394.978.000 -0.57%
2024 62.803.000 -528.92%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

STERIS plc Operating Cashflow
Year Operating Cashflow Growth
1991 -300.000
1992 -1.600.000 81.25%
1993 700.000 328.57%
1994 2.900.000 75.86%
1995 5.000.000 42%
1996 5.400.000 7.41%
1997 16.300.000 66.87%
1998 11.993.000 -35.91%
1999 64.500.000 81.41%
2000 71.107.000 9.29%
2001 102.339.000 30.52%
2002 142.023.000 27.94%
2003 133.291.000 -6.55%
2004 123.302.000 -8.1%
2005 151.389.000 18.55%
2006 161.955.000 6.52%
2007 95.740.000 -69.16%
2008 143.401.000 33.24%
2009 167.384.000 14.33%
2010 224.954.000 25.59%
2011 117.744.000 -91.05%
2012 149.372.000 21.17%
2013 227.815.000 34.43%
2014 209.631.000 -8.67%
2015 246.040.000 14.8%
2016 254.675.000 3.39%
2017 424.086.000 39.95%
2018 457.632.000 7.33%
2019 539.505.000 15.18%
2020 590.559.000 8.65%
2021 689.640.000 14.37%
2022 684.811.000 -0.71%
2023 756.947.000 9.53%
2024 146.095.000 -418.12%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

STERIS plc Capital Expenditure
Year Capital Expenditure Growth
1991 500.000
1992 700.000 28.57%
1993 1.000.000 30%
1994 2.700.000 62.96%
1995 8.800.000 69.32%
1996 10.000.000 12%
1997 20.500.000 51.22%
1998 39.181.000 47.68%
1999 118.700.000 66.99%
2000 77.131.000 -53.89%
2001 51.017.000 -51.19%
2002 65.678.000 22.32%
2003 58.592.000 -12.09%
2004 67.560.000 13.27%
2005 56.167.000 -20.28%
2006 51.170.000 -9.77%
2007 49.024.000 -4.38%
2008 56.974.000 13.95%
2009 40.889.000 -39.34%
2010 44.087.000 7.25%
2011 77.442.000 43.07%
2012 66.682.000 -16.14%
2013 87.412.000 23.72%
2014 86.367.000 -1.21%
2015 85.255.000 -1.3%
2016 126.407.000 32.56%
2017 172.901.000 26.89%
2018 165.457.000 -4.5%
2019 189.715.000 12.79%
2020 214.516.000 11.56%
2021 239.262.000 10.34%
2022 287.563.000 16.8%
2023 361.969.000 20.56%
2024 83.292.000 -334.58%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

STERIS plc Equity
Year Equity Growth
1991 1.500.000
1992 5.300.000 71.7%
1993 26.900.000 80.3%
1994 35.200.000 23.58%
1995 44.600.000 21.08%
1996 62.400.000 28.53%
1997 294.700.000 78.83%
1998 358.952.000 17.9%
1999 435.900.000 17.65%
2000 421.094.000 -3.52%
2001 424.384.000 0.78%
2002 487.145.000 12.88%
2003 569.530.000 14.47%
2004 680.699.000 16.33%
2005 755.638.000 9.92%
2006 730.827.000 -3.39%
2007 774.292.000 5.61%
2008 706.152.000 -9.65%
2009 717.736.000 1.61%
2010 754.494.000 4.87%
2011 788.665.000 4.33%
2012 822.664.000 4.13%
2013 946.980.000 13.13%
2014 1.041.246.000 9.05%
2015 1.073.646.000 3.02%
2016 3.038.892.000 64.67%
2017 2.810.033.000 -8.14%
2018 3.217.300.000 12.66%
2019 3.193.786.000 -0.74%
2020 3.419.572.000 6.6%
2021 3.901.946.000 12.36%
2022 6.556.918.000 40.49%
2023 6.097.146.000 -7.54%
2024 6.200.263.000 1.66%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

STERIS plc Assets
Year Assets Growth
1991 4.400.000
1992 8.000.000 45%
1993 30.900.000 74.11%
1994 42.700.000 27.63%
1995 54.900.000 22.22%
1996 85.400.000 35.71%
1997 539.500.000 84.17%
1998 732.325.000 26.33%
1999 866.000.000 15.44%
2000 903.574.000 4.16%
2001 844.980.000 -6.93%
2002 841.572.000 -0.4%
2003 894.992.000 5.97%
2004 1.069.810.000 16.34%
2005 1.185.722.000 9.78%
2006 1.188.973.000 0.27%
2007 1.209.170.000 1.67%
2008 1.239.292.000 2.43%
2009 1.216.939.000 -1.84%
2010 1.238.402.000 1.73%
2011 1.426.685.000 13.2%
2012 1.405.696.000 -1.49%
2013 1.761.109.000 20.18%
2014 1.887.162.000 6.68%
2015 2.099.466.000 10.11%
2016 5.346.416.000 60.73%
2017 4.924.455.000 -8.57%
2018 5.200.334.000 5.31%
2019 5.073.071.000 -2.51%
2020 5.425.582.000 6.5%
2021 6.574.471.000 17.48%
2022 11.452.599.000 42.59%
2023 10.821.839.000 -5.83%
2024 11.280.638.000 4.07%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

STERIS plc Liabilities
Year Liabilities Growth
1991 2.900.000
1992 2.700.000 -7.41%
1993 4.000.000 32.5%
1994 7.500.000 46.67%
1995 10.300.000 27.18%
1996 23.000.000 55.22%
1997 244.800.000 90.6%
1998 373.373.000 34.44%
1999 430.100.000 13.19%
2000 482.480.000 10.86%
2001 420.596.000 -14.71%
2002 354.427.000 -18.67%
2003 325.462.000 -8.9%
2004 389.111.000 16.36%
2005 430.084.000 9.53%
2006 458.146.000 6.13%
2007 434.878.000 -5.35%
2008 532.817.000 18.38%
2009 499.203.000 -6.73%
2010 483.908.000 -3.16%
2011 638.020.000 24.15%
2012 583.032.000 -9.43%
2013 814.129.000 28.39%
2014 845.916.000 3.76%
2015 1.025.820.000 17.54%
2016 2.307.524.000 55.54%
2017 2.114.422.000 -9.13%
2018 1.983.034.000 -6.63%
2019 1.887.273.000 -5.07%
2020 2.018.858.000 6.52%
2021 2.683.003.000 24.75%
2022 4.907.962.000 45.33%
2023 4.734.667.000 -3.66%
2024 5.091.470.000 7.01%

STERIS plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
52.92
Net Income per Share
5.57
Price to Earning Ratio
40.23x
Price To Sales Ratio
4.23x
POCF Ratio
26.07
PFCF Ratio
41.33
Price to Book Ratio
3.57
EV to Sales
4.84
EV Over EBITDA
31.93
EV to Operating CashFlow
29.79
EV to FreeCashFlow
47.21
Earnings Yield
0.02
FreeCashFlow Yield
0.02
Market Cap
22,13 Bil.
Enterprise Value
25,28 Bil.
Graham Number
88.59
Graham NetNet
-38.08

Income Statement Metrics

Net Income per Share
5.57
Income Quality
1.54
ROE
0.09
Return On Assets
0.05
Return On Capital Employed
0.08
Net Income per EBT
0.83
EBT Per Ebit
0.84
Ebit per Revenue
0.15
Effective Tax Rate
0.17

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.02
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.44
Operating Profit Margin
0.15
Pretax Profit Margin
0.13
Net Profit Margin
0.1

Dividends

Dividend Yield
0.01
Dividend Yield %
0.88
Payout Ratio
0.35
Dividend Per Share
1.98

Operating Metrics

Operating Cashflow per Share
8.59
Free CashFlow per Share
5.42
Capex to Operating CashFlow
-0.37
Capex to Revenue
-0.06
Capex to Depreciation
-0.57
Return on Invested Capital
0.07
Return on Tangible Assets
0.13
Days Sales Outstanding
65.65
Days Payables Outstanding
36.32
Days of Inventory on Hand
101.56
Receivables Turnover
5.56
Payables Turnover
10.05
Inventory Turnover
3.59
Capex per Share
-3.17

Balance Sheet

Cash per Share
2,16
Book Value per Share
62,65
Tangible Book Value per Share
-9.2
Shareholders Equity per Share
62.65
Interest Debt per Share
36.11
Debt to Equity
0.56
Debt to Assets
0.3
Net Debt to EBITDA
3.98
Current Ratio
2.49
Tangible Asset Value
-0,91 Bil.
Net Current Asset Value
-2,92 Bil.
Invested Capital
0.56
Working Capital
1,30 Bil.
Intangibles to Total Assets
0.63
Average Receivables
0,91 Bil.
Average Payables
0,28 Bil.
Average Inventory
794982000
Debt to Market Cap
0.16

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

STERIS plc Dividends
Year Dividends Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 2 100%
2010 1 0%
2011 1 0%
2012 1 0%
2013 1 0%
2014 1 0%
2015 1 0%
2016 1 100%
2017 1 0%
2018 1 0%
2019 1 0%
2020 2 0%
2021 2 0%
2022 2 0%
2023 2 0%

STERIS plc Profile

About STERIS plc

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

CEO
Mr. Daniel A. Carestio
Employee
17.000
Address
70 Sir John Rogerson’s Quay
Dublin, D02 R296

STERIS plc Executives & BODs

STERIS plc Executives & BODs
# Name Age
1 Mr. Andrew Xilas
Senior Vice President & GM of Dental
70
2 Kenneth E. Kohler
Senior Vice President & GM of AST
70
3 Mr. John Adam Zangerle
Senior Vice President, General Counsel & Secretary
70
4 Ms. Mary Clare Fraser
SVice President & Chief Human Resources Officer
70
5 Ms. Karen L. Burton
Chief Accounting Officer, Vice President & Controller
70
6 Mr. Michael J. Tokich
Senior Vice President & Chief Financial Officer
70
7 Mr. Cary L. Majors
Senior Vice President & President of Healthcare
70
8 Ms. Julia K. Madsen
Senior Vice President of Life Sciences
70
9 Julie Winter
Vice President of Investor Relations & Corporate Communications
70
10 Mr. Daniel A. Carestio
President, Chief Executive Officer & Director
70

STERIS plc Competitors